Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research report report published on Sunday. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also recently commented on the stock. Stephens restated an equal weight rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, April 4th. Barclays lifted their target price on shares of Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Catalent currently has a consensus rating of Hold and an average price target of $55.65.

Catalent Trading Down 0.3 %

Shares of CTLT stock opened at $56.23 on Friday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The company has a market cap of $10.18 billion, a price-to-earnings ratio of -9.22 and a beta of 1.20. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20. The firm has a fifty day moving average price of $55.56 and a 200-day moving average price of $53.96.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. As a group, equities analysts predict that Catalent will post -0.17 earnings per share for the current year.

Insider Buying and Selling

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalent

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC grew its position in Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares in the last quarter. Czech National Bank increased its position in shares of Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock valued at $1,795,000 after purchasing an additional 228 shares during the last quarter. BNP Paribas Asset Management Holding S.A. raised its holdings in Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after buying an additional 328 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its holdings in Catalent by 6.2% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after buying an additional 331 shares during the period. Finally, Arizona State Retirement System boosted its stake in Catalent by 0.7% during the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after buying an additional 365 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.